» Articles » PMID: 21985244

Stimulatory Effect of α-synuclein on the Tau-phosphorylation by GSK-3β

Overview
Journal FEBS J
Specialty Biochemistry
Date 2011 Oct 12
PMID 21985244
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Hyperphosphorylation of tau protein (tau) causes neurodegenerative diseases such as Alzheimer's disease (AD). Recent studies of the physiological correlation between tau and α-synuclein (α-SN) have demonstrated that: (a) phosphorylated tau is also present in Lewy bodies, which are cytoplasmic inclusions formed by abnormal aggregation of α-SN; and (b) the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) increases the phosphorylation of tau as well as the protein level of α-SN in cultured neuronal cells, and also in mice. However, the molecular mechanism responsible for the α-SN-mediated hyperphosphorylation of tau remains to be elucidated. In this in vitro study, we found that: (a) α-SN directly stimulates the phosphorylation of tau by glycogen synthase kinase-3β (GSK-3β), (b) α-SN forms a heterotrimeric complex with tau and GSK-3β, and (c) the nonamyloid beta component (NAC) domain and an acidic region of α-SN are responsible for the stimulation of GSK-3β-mediated tau phosphorylation. Thus, it is concluded that α-SN functions as a connecting mediator for tau and GSK-3β, resulting in GSK-3β-mediated tau phosphorylation. Because the expression of α-SN is promoted by oxidative stress, the accumulation of α-SN induced by such stress may directly induce the hyperphosphorylation of tau by GSK-3β. Furthermore, we found that heat shock protein 70 (Hsp70) suppresses the α-SN-induced phosphorylation of tau by GSK-3β through its direct binding to α-SN, suggesting that Hsp70 acts as a physiological suppressor of α-SN-mediated tau hyperphosphorylation. These results suggest that the cellular level of Hsp70 may be a novel therapeutic target to counteract α-SN-mediated tau phosphorylation in the initial stage of neurodegenerative disease.

Citing Articles

The Vital Role of Melatonin and Its Metabolites in the Neuroprotection and Retardation of Brain Aging.

Bocheva G, Bakalov D, Iliev P, Tafradjiiska-Hadjiolova R Int J Mol Sci. 2024; 25(10).

PMID: 38791160 PMC: 11121732. DOI: 10.3390/ijms25105122.


Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue.

Turkistani A, Al-Kuraishy H, Al-Gareeb A, Albuhadily A, Alexiou A, Papadakis M Mol Neurobiol. 2024; 61(9):7092-7108.

PMID: 38367137 PMC: 11338983. DOI: 10.1007/s12035-024-04003-z.


New insights into the role of GSK-3β in the brain: from neurodegenerative disease to tumorigenesis.

Lai S, Wang P, Gong J, Zhang S PeerJ. 2023; 11:e16635.

PMID: 38107562 PMC: 10722984. DOI: 10.7717/peerj.16635.


Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer's disease.

Shim K, Kang M, Youn Y, An S, Kim S Alzheimers Res Ther. 2022; 14(1):201.

PMID: 36587215 PMC: 9805257. DOI: 10.1186/s13195-022-01150-0.


Alterations in Cerebellar Microtubule Cytoskeletal Network in a ValproicAcid-Induced Rat Model of Autism Spectrum Disorders.

Gassowska-Dobrowolska M, Kolasa A, Beversdorf D, Adamczyk A Biomedicines. 2022; 10(12).

PMID: 36551785 PMC: 9776106. DOI: 10.3390/biomedicines10123031.